Results 101 to 110 of about 51,637 (256)

Assessment of length of stay and cost of minimally invasive versus open thymectomies in patients with myasthenia gravis in Florida [PDF]

, 2022
Rocio Castillo‐Larios, Daniel Hernandez‐Rojas, Aaron Spaulding, Alejandra Yu Lee‐Mateus, Priyanka Pulipaka, Dorin Colibaseanu, Mathew Thomas, Sebastián Fernández-Bussy, Ian A. Makey   +8 more
openalex   +1 more source

Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Phoebe Wellmann, Jana Zschüntzsch, Michael P. Schön, Rotraut Mössner   +3 more
wiley   +1 more source

Acute collapse in a dog with multiple autoimmune syndromes and polymyositis complicated by suspected organophosphate/carbamate toxicity

Veterinary Record Case Reports, Volume 14, Issue 1, February 2026.
Abstract A 6.5‐year‐old, spayed, female dog presented in acute respiratory distress. On admission, the dog exhibited dyspnoea, bradycardia, cyanosis and gastrointestinal signs, requiring immediate intubation and mechanical ventilation. Diagnostic evaluation revealed reduced butyrylcholinesterase activity, non‐cardiogenic pulmonary oedema, elevated ...
Sarah Hefer, Efrat Kelmer, Michal Mazaki Tovi, Dana Peery, Kobi Aharoni, Nir Edry, Sigal Klainbart   +6 more
wiley   +1 more source

Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap [PDF]

, 2023
Caroline Gosser, Anas Al Bawaliz, Waled Bahaj, Jason Chesney, Smita Ranjan   +4 more
openalex   +1 more source

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

Clinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa, Ema Rodrigues, Hiroyuki Murai   +2 more
wiley   +1 more source

Pharmacogenomics of Thiopurine Drugs: A Bench‐To‐Bedside Success Story in Thailand

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Thiopurine drugs are the cornerstone treatment for many diseases such as acute lymphoblastic leukemia (ALL), organ rejection, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other autoimmune diseases.
Mohitosh Biswas, Shobana John, Murshadul Alam Murad, Chonlaphat Sukasem   +3 more
wiley   +1 more source

Familial Autoimmune Myasthenia Gravis (Report Of 3 Cases)

Annals of Indian Academy of Neurology, 2003
Familial Autoimmune myasthenia gravis is rare, occurring in only about 1.3% cases of myasthenia gravis (MG). Here in we report a family with three family members affected by MG. Proband presented with generalised myasthenia where as the other two
Girija A. S, Madhukar M, John John K
doaj  

Myasthenia gravis with Castleman disease: A case report with review of literature

Indian Journal of Pathology and Microbiology
Myasthenia gravis is an autoimmune disorder caused by the formation of autoantibodies directed against the synapses of neuromuscular junction. It is most commonly associated with other non-thymomatous lesions. Castleman disease is one of them, which is a
Sujit Nandy, Debashis Bhattacharya, Somenath Kundu, Uttara Chatterjee   +3 more
doaj   +1 more source

Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis [PDF]

, 2010
Osamu Higuchi, Johko Hamuro, Masakatsu Motomura, Yuji Yamanashi   +3 more
openalex   +1 more source

Selective Control Assessment of the Lower Extremity for Infants and Toddlers (Mini‐SCALE): Development and validation of a clinical assessment

Developmental Medicine &Child Neurology, Volume 68, Issue 2, Page 211-217, February 2026.
The development and validation of Mini‐SCALE, an assessment of lower extremity selective motor control for young children 3 months to less than 4 years, is described. Content validity was established by expert opinion, convergent validity was shown by correlation with the Gross Motor subdomain of the DAYC‐2, and scores differed significantly for ...
Loretta A. Staudt, Barbara Sargent, Lillian Chen, Eileen G. Fowler   +3 more
wiley   +1 more source